Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 779

The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.

Trends in kinase drug discovery: targets, indications and inhibitor design

Attwood, Misty M., Fabbro, Doriano, Sokolov, Aleksandr V., Knapp, Stefan, Schiöth, Helgi B.·2021·Nature Reviews Drug Discovery

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41573-021-00252-y

Cites

240 of 240 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 240 references

Research works printed but not linked: 10

  1. Jürg Zimmermann. Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis. Future Med. Chem. 1, 1395–1398 (2009). · doi:10.4155/fmc.09.115
  2. Fabbro, D. in Inhibitors of Protein Kinases and Protein Phosphates (eds Pinna, L. A. & Cohen, P. T. W.) 361–389 (Springer, 2005).
  3. Zhang, Q., Zheng, P. & Zhu, W. Research progress of small molecule VEGFR/c-met inhibitors as anticancer agents (2016-present). Molecules 25, 2666 (2020). · doi:10.3390/molecules25112666
  4. Vu, P. & Patel, S. P. Non-small cell lung cancer targetable mutations: present and future. Precis. Cancer Med. https://doi.org/10.21037/pcm.2019.11.03 (2020). · doi:10.21037/pcm.2019.11.03
  5. Looney, A.-M., Nawaz, K. & Webster, R. M. Tumour-agnostic therapies. Nat. Rev. Drug Discov. 19, 383–384 (2020). · doi:10.1038/d41573-020-00015-1
  6. Ekambaram, R. et al. Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1. ChemMedChem 8, 909–913 (2013). · doi:10.1002/cmdc.201300042
  7. Dubost, C. Primary hyperparathyroidism: the surgical problems. A study of 1,300 operated patients. Horm. Res. 32, 101–103 (1989). · doi:10.1159/000181267
  8. Scior, T., Domeyer, D. M., Cuanalo-Contreras, K. & Laufer, S. A. Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold. Curr. Med. Chem. 18, 1526–1539 (2011). · doi:10.2174/092986711795328409
  9. Lorusso, P. et al. First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies. Ann. Oncol. 29, viii138 (2018). · doi:10.1093/annonc/mdy279.410
  10. Mauro, M. J. et al. A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). J. Clin. Oncol. 37, TPS7070–TPS7070 (2019). · doi:10.1200/jco.2019.37.15_suppl.tps7070

Cited by

See all 779

Metadata

Authors
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B.
Venue
Nature Reviews Drug Discovery
Published
2021-08-05
Volume
20
Issue
11
Pages
839-861
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W3189949217
Cited by
779
References
240
FWCI
29.57
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trends in kinase drug discovery: targets, indications and inhibitor design. https://app.cochat.ai/papers/10.1038/s41573-021-00252-y
The paper
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021). Trends in kinase drug discovery: targets, indications and inhibitor design. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-021-00252-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.